false000172312800017231282023-08-042023-08-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 28, 2025
AMNEAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | |
| Delaware | | 001-38485 | | 93-4225266 |
(State or other jurisdiction
of incorporation) | | (Commission File Number) | | (IRS Employer
Identification No.) |
400 Crossing Blvd
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (908) 947-3120
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Class A Common Stock, par value $0.01 per share | | AMRX | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| | | | | |
| Item 2.02 | Results of Operations and Financial Condition. |
On February 28, 2025, Amneal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
| | | | | |
| Item 7.01 | Regulation FD Disclosure. |
Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, February 28, 2025, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial (833) 470-1428 (in the U.S.) with access code 863159. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=77005.
The information in this report furnished pursuant to Item 7.01 shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.
| | | | | |
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibits are furnished herewith:
| | | | | | | | |
| Exhibit No. | | Description |
| | |
| | |
| 104 | | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | |
Date: February 28, 2025 | AMNEAL PHARMACEUTICALS, INC. |
| | | |
| By: | | /s/ Anastasios Konidaris |
| Name: | | Anastasios Konidaris |
| Title: | | Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer) |
Exhibit 99.1
AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
‒ Full Year 2024 Performance Met or Exceeded All Financial Guidance Metrics –
‒ Q4 2024 Net Revenue of $731 million; GAAP Net Loss of $31 million; Diluted Loss per Share of $0.10 ‒
‒ Q4 2024 Adjusted Net Income(1) of $40 million, Adjusted EBITDA(1) of $155 million; Adjusted Diluted EPS(1) of $0.12 ‒
‒ Full Year 2024 Net Revenue of $2.79 billion; GAAP Net Loss of $117 million; Diluted Loss per Share of $0.38 ‒
‒ Full Year 2024 Adjusted Net Income(1) of $187 million; Adjusted EBITDA(1) of $627 million; Adjusted Diluted EPS(1) of $0.58 ‒
‒ Provides 2025 Financial Guidance of $3.0 to $3.1 billion in net revenue and $650 to $675 million in Adjusted EBITDA(1)(2) –
BRIDGEWATER, NJ, February 28, 2025 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31, 2024.
“Amneal’s continued success in 2024 demonstrates our ability to drive sustainable growth through disciplined execution, continuous innovation, and strategic capital allocation. All three business segments achieved double-digit revenue growth, we successfully launched CREXONT®, and we reduced net leverage to 3.9x, which is one year ahead of our commitment to be below 4x. In 2025 and beyond, we are entering a new phase of growth by further expanding in high-growth areas such as Specialty, Biosimilars, and GLP-1 therapies. As a growing and diversified biopharmaceutical company, Amneal is well positioned to deliver substantial value creation for all our stakeholders,” said Chirag and Chintu Patel, Co-Chief Executive Officers.
Net revenue in the fourth quarter of 2024 was $731 million, an increase of 18% compared to $617 million in the fourth quarter of 2023. The increase was driven by Affordable Medicines(3) revenues growing 21% due to new product launches, biosimilars and multiple other complex products, AvKARE revenues growing 14% due to new product launches and Specialty revenues growing 16% driven by key branded products including CREXONT®. Net loss attributable to Amneal Pharmaceuticals, Inc. was $31 million in the fourth quarter of 2024 compared to a net loss of $99 million in the fourth quarter of 2023, which reflected the term loan refinancing in the prior year period. Adjusted EBITDA(1) in the fourth quarter of 2024 was $155 million, an increase of 9% compared to the fourth quarter of 2023, primarily due to strong revenue growth partially offset by higher spending in research and development and commercial initiatives to drive future growth. Diluted loss per share in the fourth quarter of 2024 was $0.10 compared to a loss of $0.40 for the fourth quarter of 2023, due to the aforementioned factors. Adjusted diluted EPS(1) in the fourth quarter of 2024 was $0.12 compared to $0.14 in the fourth quarter of 2023.
Net revenue for the year ended December 31, 2024 was $2.79 billion, an increase of 17% compared to $2.39 billion for the year ended December 31, 2023. Each of the business segments grew revenues double-digits in 2024 driven by the success of new product launches across the segments with Affordable Medicines(3) growing 15%, AvKARE growing 25% and Specialty growing 14%. Net loss attributable to Amneal Pharmaceuticals, Inc. was $117 million for the year ended December 31, 2024 compared to a net loss of $84 million for the year ended December 31, 2023, primarily due to higher operating income offset by higher interest expense. Adjusted EBITDA(1) for the year ended December 31, 2024 was $627 million, an increase of 12% compared to the prior year, reflective of strong revenue growth and consistent adjusted gross margins, partially offset by select investments in research and development and commercial initiatives for new products to drive future growth. Diluted loss per share for the year ended December 31, 2024 was $0.38 compared to diluted loss per share of $0.48 for the year ended December 31, 2023, due to increased operating income more than offset by higher interest expense. Adjusted diluted EPS(1) in the year ended December 31, 2024 was $0.58, a decrease of 9% from $0.64 for the year ended December 31, 2023.
(1) See “Non-GAAP Financial Measures” below.
(2) The Company cannot provide a reconciliation between projected adjusted EBITDA and net income (loss), the most directly comparable measure in accordance with GAAP, without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.
(3) During the fourth quarter of 2024, the Company changed the name of its Generics segment to “Affordable Medicines” to reflect the full product offering of the segment. The Affordable Medicines segment includes retail generics, injectables, biosimilars and international net revenues. The name change did not result in any change to the composition of the Company’s reportable segments and, therefore, did not result in any change to its historical results.
2025 Financial Guidance
| | | | | | | | |
| Full Year 2025 Guidance | Full Year 2024 Actuals |
| Net revenue | $3.0 billion - $3.1 billion | $2.79 billion |
Adjusted EBITDA (1) | $650 million - $675 million | $627 million |
Adjusted diluted EPS (2) | $0.65 - $0.70 | $0.58 |
Operating cash flow | $255 million - $285 million | $295 million |
Operating cash flow, excluding discrete items (3) | $280 million - $310 million | $348 million |
Capital expenditures (4) | Approximately $100 million | $52 million |
(1)Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial Measures” below.
(2)Accounts for 35% non-controlling interest in AvKARE. Assumes weighted-average diluted shares outstanding of approximately 330 million for the year ending December 31, 2025, compared to weighted-average diluted shares outstanding of 321 million for the year ended December 31, 2024. See also “Non-GAAP Financial Measures” below for assumptions used in the calculation of weighted-average diluted shares.
(3)Excludes discrete items such as legal settlement payments. 2024 actuals exclude the final settlement payment for the Opana ER® antitrust litigation of $52 million.
(4)Reflects estimated capital expenditures, net of expected contributions from an alliance partner of $20 million.
Amneal’s 2025 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.
Conference Call Information
Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, February 28, 2025, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial (833) 470-1428 (in the U.S.) with access code 863159. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=77005.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceutical products, primarily within the United States. In our Affordable Medicines segment, we are expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In our Specialty segment, we have a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.
Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; statements regarding our expansion into high-growth areas and statements regarding our positioning, including our ability to drive sustainable value creation, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.
The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results,
operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.
Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; the imposition of tariffs may adversely affect our business, results of operations and financial condition; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our dependence on third-party agreements for a portion of our product offerings; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our class A common stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.
Non-GAAP Financial Measures
This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted operating cash flow and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP. Adjusted diluted EPS reflects diluted earnings per share based on adjusted net income, which is net loss adjusted to (A) exclude (i) non-cash interest, (ii) GAAP provision for income taxes, (iii) amortization, (iv) stock-based compensation expense, (v) acquisition, site closure expenses, and idle facility expenses, (vi) restructuring and other charges, (vii) loss on refinancing, (viii) charges related to certain legal matters, including interest, net, (ix) asset impairment charges, (x) change in fair value of contingent consideration, (xi) increase in tax receivable agreement liability, (xii) system implementation expense, (xiii) Reorganization expenses, (xiv) other and (xv) net income attributable to non-controlling interests not associated with our Class B common stock, and (B) includes non-GAAP provision for income taxes. Non-GAAP adjusted diluted EPS for the three months and year ended December 31, 2024 was calculated using the weighted average fully diluted shares outstanding of Class A common stock (inclusive of the effect of dilutive securities). Non-GAAP adjusted diluted EPS for the three months and year ended December 31, 2023 was calculated using the weighted average diluted shares outstanding of Class A common stock (inclusive of the effect of dilutive securities) and assuming all shares of Class B common stock were converted to shares of Class A common stock as of January 1, 2023. Adjusted EBITDA reflects net loss adjusted to exclude (i) interest expense, net, (ii) provision for income taxes, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) acquisition, site closure, and idle facility expenses, (vi) restructuring and other charges, (vii) loss on refinancing (viii) charges related to legal matters, net, (ix) asset impairment charges, (x) foreign exchange loss (gain), (xi) change in fair value of contingent consideration, (xii) increase in tax receivable agreement liability, (xiii) system implementation expense, (xiv) Reorganization expense, and (xv) other. Net leverage is calculated as net debt (total outstanding principal on the Company’s debt, less cash and cash equivalents), divided by adjusted EBITDA for the year or trailing twelve months then ended.
Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of
directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations, cash flows, net leverage and trends while viewing the information through the eyes of management.
These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.
A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.
Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
Amneal Pharmaceuticals, Inc.
Consolidated Statements of Operations
(unaudited; $ in thousands, except per share amounts)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended December 31, | | Year Ended
December 31, |
| 2024 | | 2023 | | 2024 | | 2023 |
| Net revenue | $ | 730,518 | | | $ | 616,981 | | | $ | 2,793,957 | | | $ | 2,393,607 | |
| Cost of goods sold | 467,645 | | | 427,154 | | | 1,773,519 | | | 1,573,042 | |
| Gross profit | 262,873 | | | 189,827 | | | 1,020,438 | | | 820,565 | |
| Selling, general and administrative | 128,687 | | | 109,003 | | | 476,436 | | | 429,675 | |
| Research and development | 54,265 | | | 46,086 | | | 190,714 | | | 163,950 | |
| In-process research and development impairment charges | — | | | 30,800 | | | — | | | 30,800 | |
| Intellectual property legal development expenses | 1,852 | | | 478 | | | 5,845 | | | 3,828 | |
| Restructuring and other charges | 493 | | | 114 | | | 2,355 | | | 1,749 | |
| Change in fair value of contingent consideration | — | | | (13,710) | | | (930) | | | (14,497) | |
| Charges related to legal matters, net | 1,783 | | | 2,863 | | | 96,692 | | | 1,824 | |
| Other operating income | — | | | — | | | — | | | (1,138) | |
Operating income | 75,793 | | | 14,193 | | | 249,326 | | | 204,374 | |
| Other (expense) income: | | | | | | | |
| Interest expense, net | (61,662) | | | (59,548) | | | (258,595) | | | (210,629) | |
Foreign exchange (loss) gain, net | (7,661) | | | 2,288 | | | (6,846) | | | 1,671 | |
| Loss on refinancing | — | | | (40,805) | | | — | | | (40,805) | |
| Increase in tax receivable agreement liability | (23,961) | | | (1,217) | | | (50,680) | | | (3,124) | |
| Other income, net | 2,172 | | | 1,628 | | | 11,782 | | | 8,243 | |
| Total other expense, net | (91,112) | | | (97,654) | | | (304,339) | | | (244,644) | |
Loss before income taxes | (15,319) | | | (83,461) | | | (55,013) | | | (40,270) | |
Provision for income taxes | 5,423 | | | 9,883 | | | 18,863 | | | 8,452 | |
Net loss | (20,742) | | | (93,344) | | | (73,876) | | | (48,722) | |
Less: Net income attributable to non-controlling interests | (10,339) | | | (5,305) | | | (43,010) | | | (35,271) | |
Net loss attributable to Amneal Pharmaceuticals, Inc. | $ | (31,081) | | | $ | (98,649) | | | $ | (116,886) | | | $ | (83,993) | |
| | | | | | | |
| Net loss per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders: | | | | | | | |
Basic and diluted | $ | (0.10) | | | $ | (0.40) | | | $ | (0.38) | | | $ | (0.48) | |
Weighted-average common shares outstanding(1): | | | | | | | |
Basic and diluted | 309,850 | | | 243,711 | | | 308,978 | | | 176,136 | |
(1)On November 7, 2023, the Company implemented a plan to reorganize and simplify its corporate structure by eliminating its umbrella partnership-C-corporation structure and converting to a more traditional C-corporation structure, whereby all stockholders hold their voting and economic interests directly through the public company (the “Reorganization”). Following the implementation of the Reorganization, all outstanding shares of Old PubCo Class A Common Stock and Old PubCo Class B Common Stock were exchanged for an equivalent number of shares of Class A common stock of the Company. Refer to Note 1. Nature of Operations and Note 8. (Loss) Earnings per Share to the consolidated financial statements in the Company’s 2023 Annual Report on Form 10-K for additional information.
Amneal Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(unaudited; $ in thousands)
| | | | | | | | | | | |
| December 31,
2024 | | December 31,
2023 |
| Assets | | | |
| Current assets: | | | |
| Cash and cash equivalents | $ | 110,552 | | | $ | 91,542 | |
| Restricted cash | 7,868 | | | 7,565 | |
| Trade accounts receivable, net | 775,731 | | | 613,732 | |
| Inventories | 612,454 | | | 581,384 | |
| Prepaid expenses and other current assets | 80,717 | | | 82,685 | |
| Related party receivables | 484 | | | 955 | |
| Total current assets | 1,587,806 | | | 1,377,863 | |
| Property, plant and equipment, net | 424,908 | | | 447,574 | |
| Goodwill | 597,436 | | | 598,629 | |
| Intangible assets, net | 732,377 | | | 890,423 | |
| Operating lease right-of-use assets | 31,388 | | | 30,329 | |
| Operating lease right-of-use assets - related party | 10,964 | | | 12,954 | |
| Financing lease right-of-use assets | 56,433 | | | 59,280 | |
| Other assets | 60,133 | | | 55,517 | |
| Total assets | $ | 3,501,445 | | | $ | 3,472,569 | |
| Liabilities and Stockholders’ (Deficiency) Equity | | | |
| Current liabilities: | | | |
| Accounts payable and accrued expenses | $ | 735,450 | | | $ | 534,662 | |
| Current portion of liabilities for legal matters | 31,755 | | | 76,988 | |
| Revolving credit facility | 100,000 | | | 179,000 | |
| Current portion of long-term debt, net | 224,213 | | | 34,125 | |
| Current portion of operating lease liabilities | 9,435 | | | 9,207 | |
| Current portion of operating lease liabilities - related party | 3,396 | | | 2,825 | |
| Current portion of financing lease liabilities | 3,211 | | | 2,467 | |
| Related party payables - short term | 22,311 | | | 7,321 | |
| Total current liabilities | 1,129,771 | | | 846,595 | |
| Long-term debt, net | 2,161,790 | | | 2,386,004 | |
| Note payable - related party | — | | | 41,447 | |
| Operating lease liabilities | 24,814 | | | 24,095 | |
| Operating lease liabilities - related party | 9,391 | | | 12,787 | |
| Financing lease liabilities | 56,889 | | | 58,566 | |
| Related party payable - long term | 50,900 | | | 11,776 | |
| Liabilities for legal matters - long term | 85,479 | | | 316 | |
| Other long-term liabilities | 26,949 | | | 29,679 | |
| Total long-term liabilities | 2,416,212 | | | 2,564,670 | |
| Redeemable non-controlling interests | 64,974 | | | 41,293 | |
| Total stockholders' (deficiency) equity | (109,512) | | | 20,011 | |
| Total liabilities and stockholders' (deficiency) equity | $ | 3,501,445 | | | $ | 3,472,569 | |
Amneal Pharmaceuticals, Inc.
Consolidated Statements of Cash Flows
(unaudited; $ in thousands) | | | | | | | | | | | |
| Years Ended December 31, |
| 2024 | | 2023 |
| Cash flows from operating activities: | | | |
| Net loss | $ | (73,876) | | | $ | (48,722) | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | | | |
| Depreciation and amortization | 236,191 | | | 229,400 | |
| Unrealized foreign currency loss (gain) | 7,191 | | | (768) | |
| Amortization of debt issuance costs and discount | 29,097 | | | 11,548 | |
| Reclassification of cash flow hedge | (26,205) | | | (3,366) | |
Loss on refinancing | — | | | 40,805 | |
| Intangible asset impairment charges | 920 | | | 66,932 | |
| Change in fair value of contingent consideration | (930) | | | (14,497) | |
| Stock-based compensation | 27,768 | | | 26,822 | |
| Inventory provision | 96,558 | | | 74,686 | |
| Other operating charges and credits, net | 2,453 | | | 9,923 | |
| Changes in assets and liabilities: | | | |
| Trade accounts receivable, net | (162,637) | | | 126,289 | |
| Inventories | (130,530) | | | (126,182) | |
| Prepaid expenses, other current assets and other assets | (959) | | | 37,814 | |
| Related party receivables | 482 | | | (490) | |
| Accounts payable, accrued expenses and other liabilities | 235,135 | | | (94,446) | |
| Related party payables | 54,441 | | | 9,829 | |
| Net cash provided by operating activities | 295,099 | | | 345,577 | |
| Cash flows from investing activities: | | | |
| Purchases of property, plant and equipment | (51,924) | | | (43,216) | |
| Acquisition of intangible assets | (14,650) | | | (22,388) | |
| Deposits for future acquisition of property, plant, and equipment | (8,416) | | | (3,585) | |
| Proceeds from sale of subsidiary | 11,994 | | | — | |
| Net cash used in investing activities | (62,996) | | | (69,189) | |
| Cash flows from financing activities: | | | |
| Payments of deferred financing, refinancing costs and debt extinguishment costs | (71) | | | (162,415) | |
| Payments of principal on debt, revolving credit facility, financing leases and other | (188,918) | | | (414,080) | |
| Proceeds from issuance of debt | — | | | 217,732 | |
| Borrowings on revolving credit facility | 48,000 | | | 219,000 | |
| Proceeds from exercise of stock options | 1,154 | | | 451 | |
| Employee payroll tax withholding on restricted stock unit vesting | (7,952) | | | (2,378) | |
| Tax distributions to non-controlling interest | (19,804) | | | (70,883) | |
| Repayment of related party note | (44,200) | | | — | |
| Net cash used in financing activities | (211,791) | | | (212,573) | |
| Effect of foreign exchange rate on cash | (999) | | | 65 | |
Net increase in cash, cash equivalents, and restricted cash | 19,313 | | | 63,880 | |
| Cash, cash equivalents, and restricted cash - beginning of period | 99,107 | | | 35,227 | |
| Cash, cash equivalents, and restricted cash - end of period | $ | 118,420 | | | $ | 99,107 | |
| Cash and cash equivalents - end of period | $ | 110,552 | | | $ | 91,542 | |
| Restricted cash - end of period | 7,868 | | | 7,565 | |
| Cash, cash equivalents, and restricted cash - end of period | $ | 118,420 | | | $ | 99,107 | |
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited, $ in thousands)
Reconciliation of Net Loss to EBITDA and Adjusted EBITDA
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended December 31, | | Year Ended December 31, |
| 2024 | | 2023 | | 2024 | | 2023 |
| Net loss | $ | (20,742) | | | $ | (93,344) | | | $ | (73,876) | | | $ | (48,722) | |
| Adjusted to add (deduct): | | | | | | | |
| Interest expense, net | 61,662 | | | 59,548 | | | 258,595 | | | 210,629 | |
| Provision for income taxes | 5,423 | | | 9,883 | | | 18,863 | | | 8,452 | |
| Depreciation and amortization | 66,130 | | | 56,933 | | | 236,191 | | | 229,400 | |
| EBITDA (Non-GAAP) | $ | 112,473 | | | $ | 33,020 | | | $ | 439,773 | | | $ | 399,759 | |
| Adjusted to add (deduct): | | | | | | | |
| Stock-based compensation expense | 7,209 | | | 5,974 | | | 27,552 | | | 26,822 | |
Acquisition, site closure, and idle facility expenses (1) | 538 | | | 1,186 | | | 2,112 | | | 7,017 | |
| Restructuring and other charges | 493 | | | 114 | | | 2,265 | | | 1,650 | |
| Loss on refinancing | — | | | 40,805 | | | — | | | 40,805 | |
Charges related to legal matters, net (2) | 1,783 | | | 2,863 | | | 96,692 | | | 11,824 | |
Asset impairment charges (3) | 176 | | | 67,228 | | | 1,372 | | | 70,107 | |
| Foreign exchange loss (gain) | 7,661 | | | (2,288) | | | 6,846 | | | (1,671) | |
| Change in fair value of contingent consideration | — | | | (13,710) | | | (930) | | | (14,497) | |
| Increase in tax receivable agreement liability | 23,961 | | | 1,217 | | | 50,680 | | | 3,124 | |
System implementation expense (4) | 337 | | | 934 | | | 2,366 | | | 5,363 | |
Reorganization expenses (5) | — | | | 4,630 | | | — | | | 5,927 | |
| Other | 626 | | | 175 | | | (1,286) | | | 1,984 | |
| Adjusted EBITDA (Non-GAAP) | $ | 155,257 | | | $ | 142,148 | | | $ | 627,442 | | | $ | 558,214 | |
Calculation of Net Leverage
| | | | | | | | | | | |
| December 31, 2024 | | December 31, 2023 |
Term Loan Due 2025 | $ | 191,979 | | | $ | 191,979 | |
Term Loan Due 2028 | 2,292,856 | | | 2,351,647 | |
Amended New Revolving Credit Facility | 100,000 | | | 179,000 | |
Sellers Notes | — | | | 44,200 | |
| Gross debt | $ | 2,584,835 | | | $ | 2,766,826 | |
| Less: Cash and cash equivalents | 110,552 | | | 91,542 | |
Net debt (Non-GAAP) (6) | $ | 2,474,283 | | | $ | 2,675,284 | |
| | | |
Adjusted EBITDA (Non-GAAP) for the year ended | $ | 627,442 | | | $ | 558,214 | |
| | | |
Net leverage (Non-GAAP) (7) | 3.9x | | 4.8x |
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited; $ in thousands, except per share amounts)
Reconciliation of Net Loss to Adjusted Net Income and Calculation of Adjusted Diluted Earnings per Share
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended December 31, | | Year Ended December 31, |
| 2024 | | 2023 | | 2024 | | 2023 |
Net loss | $ | (20,742) | | | $ | (93,344) | | | $ | (73,876) | | | $ | (48,722) | |
| Adjusted to add (deduct): | | | | | | | |
Non-cash interest | 183 | | | 1,016 | | | 1,735 | | | 7,017 | |
GAAP provision for income taxes | 5,423 | | | 9,883 | | | 18,863 | | | 8,452 | |
Amortization | 49,037 | | | 39,208 | | | 168,518 | | | 157,219 | |
Stock-based compensation expense | 7,209 | | | 5,974 | | | 27,552 | | | 26,822 | |
Acquisition, site closure expenses, and idle facility expenses (1) | 538 | | | 1,186 | | | 2,112 | | | 7,017 | |
Restructuring and other charges | 493 | | | 114 | | | 2,249 | | | 1,650 | |
| Loss on refinancing | — | | | 40,805 | | | — | | | 40,805 | |
Charges related to legal matters, including interest, net (2) | 1,783 | | | 3,580 | | | 96,819 | | | 14,784 | |
Asset impairment charges (3) | 176 | | | 67,143 | | | 1,372 | | | 70,015 | |
| Change in fair value of contingent consideration | — | | | (13,710) | | | (930) | | | (14,497) | |
| Increase in tax receivable agreement liability | 23,961 | | | 1,217 | | | 50,680 | | | 3,124 | |
System implementation expense (4) | 337 | | | 934 | | | 2,366 | | | 5,363 | |
Reorganization expenses (5) | — | | | 4,630 | | | — | | | 5,927 | |
| Other | 627 | | | 323 | | | (1,286) | | | 2,466 | |
Provision for income taxes (8) | (18,262) | | | (17,563) | | | (66,278) | | | (60,014) | |
| Net income attributable to non-controlling interests not associated with our class B common stock | (10,339) | | | (7,831) | | | (43,010) | | | (29,873) | |
| Adjusted net income (Non-GAAP) | $ | 40,424 | | | $ | 43,565 | | | $ | 186,886 | | | $ | 197,555 | |
Weighted average diluted shares outstanding (Non-GAAP) (9) | 324,099 | | | 314,986 | | | 320,645 | | | 310,234 | |
| Adjusted diluted earnings per share (Non-GAAP) | $ | 0.12 | | | $ | 0.14 | | | $ | 0.58 | | | $ | 0.64 | |
Amneal Pharmaceuticals, Inc.
Non-GAAP Reconciliations
(unaudited)
Explanations for Non-GAAP Reconciliations
(1)Acquisition, site closure, and idle facility expenses for the three months and year ended December 31, 2024 primarily included rent for vacated properties. Acquisition, site closure, and idle facility expenses for the three months and year ended December 31, 2023 primarily included site closure costs associated with the planned cessation of manufacturing at our Hauppauge, NY facility.
(2)For the year ended December 31, 2024, charges related to legal matters, net were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by political subdivisions and Native American tribes across the United States. For the three months ended December 31, 2023, charges related to legal matters, net were primarily comprised of a settlement of commercial antitrust litigation. For the year ended December 31, 2023, charges related to legal matters, net were primarily comprised of (i) charges associated with civil prescription opioid litigation, (ii) a settlement of a customer claim, (iii) a settlement of commercial antitrust litigation, and (iv) a settlement of a stockholder derivative lawsuit.
(3)Asset impairment charges for the three months and year ended December 31, 2023 were primarily associated with the write-offs of intangibles assets.
(4)System implementation expense for the three months and year ended December 31, 2024 and 2023 was primarily for the implementation of software to further integrate our acquired businesses.
(5)For the three months and year ended December 31, 2023, Reorganization expenses were comprised of professional fees.
(6)Net debt was calculated as the total outstanding principal on the Company’s debt less cash and cash equivalents.
(7)Net leverage was calculated by dividing net debt as of December 31, 2024 and 2023 by adjusted EBITDA for the years ended December 31, 2024 and 2023, respectively.
(8)The non-GAAP effective tax rates for the three months and year ended December 31, 2024 were 31.1% and 26.2%, respectively. The non-GAAP effective tax rates for the three months and year ended December 31, 2023 were 28.7% and 23.3%, respectively.
(9)Weighted average diluted shares outstanding for the three months and year ended December 31, 2024 consisted of fully diluted Class A common stock (inclusive of the effect of dilutive securities). Weighted average diluted shares outstanding for the three months and year ended December 31, 2023 consisted of fully diluted Class A common stock (inclusive of the effect of dilutive securities) and Class B common stock, as if all shares of Class B common stock were converted to Class A common stock as of January 1, 2023.
Amneal Pharmaceuticals, Inc.
Affordable Medicines Segment
Reconciliation of GAAP to Non-GAAP Operating Results (1)
(unaudited; $ in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended December 31, 2024 | | Three Months Ended December 31, 2023 |
| | As Reported | | Adjustments | | Non-GAAP | | As Reported | | Adjustments | | Non-GAAP |
| Net revenue | | $ | 439,296 | | | $ | — | | | $ | 439,296 | | | $ | 363,037 | | | $ | — | | | $ | 363,037 | |
Cost of goods sold (2) | | 261,196 | | | (11,595) | | | 249,601 | | | 221,861 | | | (14,167) | | | 207,694 | |
| Gross profit | | 178,100 | | | 11,595 | | | 189,695 | | | 141,176 | | | 14,167 | | | 155,343 | |
| Gross margin % | | 40.5 | % | | | | 43.2 | % | | 38.9 | % | | | | 42.8 | % |
| | | | | | | | | | | | |
Selling, general and administrative (3) | | 33,915 | | | (1,909) | | | 32,006 | | | 30,734 | | | (1,849) | | | 28,885 | |
Research and development (4) | | 48,598 | | | (674) | | | 47,924 | | | 33,663 | | | (654) | | | 33,009 | |
| In-process research and development impairment charges | | — | | | — | | | — | | | 26,500 | | | (26,500) | | | — | |
| Intellectual property legal development expenses | | 1,907 | | | — | | | 1,907 | | | 468 | | | — | | | 468 | |
| Charges related to legal matters, net | | 1,783 | | | (1,783) | | | — | | | 2,863 | | | (2,863) | | | — | |
| Operating income | | $ | 91,897 | | | $ | 15,961 | | | $ | 107,858 | | | $ | 46,948 | | | $ | 46,033 | | | $ | 92,981 | |
(1)Operating results for the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)Adjustments for the three months ended December 31, 2024 and 2023, respectively, were comprised of stock-based compensation expense ($0.9 million and $0.6 million), amortization expense ($10.6 million and $10.7 million), site closure and idle facility expenses (none and $0.7 million), asset impairment charges ($0.1 million and $2.3 million), and other (none and $(0.1) million).
(3)Adjustments for the three months ended December 31, 2024 and 2023, respectively, were comprised of stock-based compensation expense ($1.4 million and $1.2 million) and site closure costs ($0.5 million and $0.6 million).
(4)Adjustments for the three months ended December 31, 2024 and 2023 were comprised of stock-based compensation expense.
Amneal Pharmaceuticals, Inc.
Affordable Medicines Segment
Reconciliation of GAAP to Non-GAAP Operating Results (1)
(unaudited; $ in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Year Ended December 31, 2024 | | Year Ended December 31, 2023 |
| | As Reported | | Adjustments | | Non-GAAP | | As Reported | | Adjustments | | Non-GAAP |
| Net revenue | | $ | 1,685,263 | | | $ | — | | | $ | 1,685,263 | | | $ | 1,471,401 | | | $ | — | | | $ | 1,471,401 | |
Cost of goods sold (2) | | 1,011,363 | | (46,718) | | | 964,645 | | 913,869 | | (56,450) | | | 857,419 |
| Gross profit | | 673,900 | | 46,718 | | | 720,618 | | 557,532 | | 56,450 | | | 613,982 |
| Gross margin % | | 40.0 | % | | | | 42.8 | % | | 37.9 | % | | | | 41.7 | % |
| | | | | | | | | | | | |
Selling, general and administrative (3) | | 129,578 | | (7,160) | | | 122,418 | | 119,912 | | (7,411) | | | 112,501 |
Research and development (4) | | 171,771 | | (2,587) | | | 169,184 | | 132,233 | | (2,555) | | | 129,678 |
| In-process research and development impairment charges | | — | | — | | | — | | 26,500 | | (26,500) | | | — |
| Intellectual property legal development expenses | | 5,685 | | — | | | 5,685 | | 3,708 | | — | | | 3,708 |
| Restructuring and other charges | | 70 | | (70) | | | — | | 211 | | (112) | | | 99 |
Charges (credit) related to legal matters, net (5) | | 96,692 | | (96,692) | | | — | | (64) | | (9,936) | | | (10,000) |
| Other operating income | | — | | — | | | — | | (1,138) | | — | | | (1,138) |
| Operating income | | $ | 270,104 | | $ | 153,227 | | | $ | 423,331 | | $ | 276,170 | | $ | 102,964 | | | $ | 379,134 |
(1)Operating results for the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)Adjustments for the years ended December 31, 2024 and 2023, respectively, were comprised of stock-based compensation expense ($3.6 million and $3.5 million), amortization expense ($41.8 million and $42.8 million), site closure and idle facility expenses (none and $4.9 million), asset impairment charges ($1.3 million and $5.2 million), and other (none million and $0.1 million).
(3)Adjustments for the years ended December 31, 2024 and 2023, respectively, were comprised of stock-based compensation expense ($5.1 million, and $5.2 million) and site closure expenses ($2.1 million and $2.2 million).
(4)Adjustments for the years ended December 31, 2024 and 2023 were comprised of stock-based compensation expense.
(5)Adjustment for the year ended December 31, 2024 was primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against the Company by political subdivisions and Native American tribes across the United States.
Amneal Pharmaceuticals, Inc.
Specialty Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(unaudited; $ in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended December 31, 2024 | | Three Months Ended December 31, 2023 |
| As Reported | | Adjustments | | Non-GAAP | | As Reported | | Adjustments | | Non-GAAP |
| Net revenue | $ | 120,836 | | $ | — | | | $ | 120,836 | | $ | 104,481 | | $ | — | | | $ | 104,481 |
Cost of goods sold (1) | 59,537 | | (36,224) | | | 23,313 | | 79,023 | | (59,940) | | | 19,083 |
| Gross profit | 61,299 | | 36,224 | | | 97,523 | | 25,458 | | 59,940 | | | 85,398 |
| Gross margin % | 50.7 | % | | | | 80.7 | % | | 24.4 | % | | | | 81.7 | % |
| | | | | | | | | | | |
Selling, general and administrative (2) | 30,129 | | (293) | | | 29,836 | | 20,243 | | (39) | | | 20,204 |
Research and development (2) | 5,667 | | (257) | | | 5,410 | | 12,423 | | (451) | | | 11,972 |
| In-process research and development impairment charges | — | | — | | | — | | 4,300 | | (4,300) | | | — |
| Intellectual property legal development expenses | (55) | | — | | | (55) | | 10 | | — | | | 10 |
| Restructuring and other charges | 493 | | (493) | | | — | | 92 | | (92) | | | — |
Change in fair value of contingent consideration (3) | — | | — | | | — | | (13,710) | | 13,710 | | | — |
| Operating income | $ | 25,065 | | $ | 37,267 | | | $ | 62,332 | | $ | 2,100 | | $ | 51,112 | | | $ | 53,212 |
(1)Adjustments for the three months ended December 31, 2024 and 2023, respectively, were comprised of amortization expense ($36.2 million and $25.8 million) and asset impairment charges (none and $34.1 million).
(2)Adjustments for the three months ended December 31, 2024 and 2023 were comprised of stock-based compensation expense.
(3)Contingent consideration was recorded in connection with the acquisitions of (i) the baclofen franchise from certain entities affiliated with Saol International Limited and (ii) Kashiv Specialty Pharmaceuticals, LLC.
Amneal Pharmaceuticals, Inc.
Specialty Segment
Reconciliation of GAAP to Non-GAAP Operating Results
(unaudited; $ in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Year Ended December 31, 2024 | | Year Ended December 31, 2023 |
| As Reported | | Adjustments | | Non-GAAP | | As Reported | | Adjustments | | Non-GAAP |
| Net revenue | $ | 445,749 | | | $ | — | | | $ | 445,749 | | | $ | 390,457 | | | $ | — | | | $ | 390,457 | |
Cost of goods sold (1) | 202,821 | | | (117,573) | | | 85,248 | | | 214,277 | | | (137,811) | | | 76,466 | |
| Gross profit | 242,928 | | | 117,573 | | | 360,501 | | | 176,180 | | | 137,811 | | | 313,991 | |
| Gross margin % | 54.5 | % | | | | 80.9 | % | | 45.1 | % | | | | 80.4 | % |
| | | | | | | | | | | |
Selling, general and administrative (2) | 109,658 | | | (1,048) | | | 108,610 | | | 88,137 | | | (688) | | | 87,449 | |
Research and development (2) | 18,943 | | | (1,058) | | | 17,885 | | | 31,717 | | | (1,785) | | | 29,932 | |
| In-process research and development impairment charges | — | | | — | | | — | | | 4,300 | | | (4,300) | | | — | |
| Intellectual property legal development expenses | 160 | | | — | | | 160 | | | 120 | | | — | | | 120 | |
| Restructuring and other charges | 1,517 | | | (1,517) | | | — | | | 1,105 | | | (1,105) | | | — | |
Change in fair value of contingent consideration (3) | (930) | | | 930 | | | — | | | (14,497) | | | 14,497 | | | — | |
| Operating income | $ | 113,580 | | | $ | 120,266 | | | $ | 233,846 | | | $ | 65,298 | | | $ | 131,192 | | | $ | 196,490 | |
(1)Adjustments for the years ended December 31, 2024 and 2023, respectively, were comprised of amortization expense ($117.6 million and $103.7 million) and asset impairment charges (none and $34.1 million).
(2)Adjustments for the years ended December 31, 2024 and 2023 were comprised of stock-based compensation expense.
(3)Contingent consideration was recorded in connection with the acquisitions of (i) the baclofen franchise from certain entities affiliated with Saol International Limited and (ii) Kashiv Specialty Pharmaceuticals, LLC.
Amneal Pharmaceuticals, Inc.
AvKARE Segment
Reconciliation of GAAP to Non-GAAP Operating Results (1)
(unaudited; $ in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended December 31, 2024 | | Three Months Ended December 31, 2023 |
| As Reported | | Adjustments | | Non-GAAP | | As Reported | | Adjustments | | Non-GAAP |
| Net revenue | $ | 170,386 | | | $ | — | | | $ | 170,386 | | | $ | 149,463 | | | $ | — | | | $ | 149,463 | |
| Cost of goods sold | 146,912 | | | — | | | 146,912 | | | 126,270 | | | — | | | 126,270 | |
| Gross profit | 23,474 | | | — | | | 23,474 | | | 23,193 | | | — | | | 23,193 | |
| Gross margin % | 13.8 | % | | | | 13.8 | % | | 15.5 | % | | | | 15.5 | % |
| | | | | | | | | | | |
Selling, general and administrative (2) | 16,015 | | | (3,546) | | | 12,469 | | | 14,073 | | | (3,764) | | | 10,309 | |
| Operating income | $ | 7,459 | | | $ | 3,546 | | | $ | 11,005 | | | $ | 9,120 | | | $ | 3,764 | | | $ | 12,884 | |
(1)Operating results for the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)Adjustments for the three months ended December 31, 2024 and 2023, respectively, were comprised of amortization expense ($3.6 million and $4.2 million) and other (none and $(0.4) million).
Amneal Pharmaceuticals, Inc.
AvKARE Segment
Reconciliation of GAAP to Non-GAAP Operating Results (1)
(unaudited; $ in thousands)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Year Ended December 31, 2024 | | Year Ended December 31, 2023 |
| As Reported | | Adjustments | | Non-GAAP | | As Reported | | Adjustments | | Non-GAAP |
| Net revenue | $ | 662,945 | | | $ | — | | | $ | 662,945 | | | $ | 531,749 | | | $ | — | | | $ | 531,749 | |
| Cost of goods sold | 559,335 | | | — | | | 559,335 | | | 444,896 | | | — | | | 444,896 | |
| Gross profit | 103,610 | | | — | | | 103,610 | | | 86,853 | | | — | | | 86,853 | |
| Gross margin % | 15.6 | % | | | | 15.6 | % | | 16.3 | % | | | | 16.3 | % |
| | | | | | | | | | | |
Selling, general and administrative (2) | 60,709 | | | (14,182) | | | 46,527 | | | 55,341 | | | (15,373) | | | 39,968 | |
| Operating income | $ | 42,901 | | | $ | 14,182 | | | $ | 57,083 | | | $ | 31,512 | | | $ | 15,373 | | | $ | 46,885 | |
(1)Operating results for the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)Adjustments for the years ended December 31, 2024 and 2023, respectively, were comprised of amortization ($14.2 million and $16.8 million) and other (none and $(1.4) million).
v3.25.0.1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Amneal Pharmaceuticals (NASDAQ:AMRX)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Amneal Pharmaceuticals (NASDAQ:AMRX)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
